For investor-related information please contact Ronn Bechler at Automic Group
Ph: +61 (0) 400 009 774 E: email@example.com
H&P’s updated report on Zelira highlighted by the completed enrolment of participants in the diabetic nerve pain trial
Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.
Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.
Zelira to launch a suite of new cannabinoid-based products in FY22 – Proactive
Zelira Therapeutics and Curtin University partner on research of proprietary technology that demonstrates significant uptake of CBD into the brain
Zelira Therapeutics Investor Slide Deck
Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC
Start typing and press Enter to search